Supriya Lifescience Limited

NSE SUPRIYA.NS

Supriya Lifescience Limited EBITDA for the year ending March 31, 2024: USD 22.01 M

Supriya Lifescience Limited EBITDA is USD 22.01 M for the year ending March 31, 2024, a 30.71% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Supriya Lifescience Limited EBITDA for the year ending March 31, 2023 was USD 16.84 M, a -42.30% change year over year.
  • Supriya Lifescience Limited EBITDA for the year ending March 31, 2022 was USD 29.18 M, a 19.93% change year over year.
  • Supriya Lifescience Limited EBITDA for the year ending March 31, 2021 was USD 24.33 M, a 68.27% change year over year.
  • Supriya Lifescience Limited EBITDA for the year ending March 31, 2020 was USD 14.46 M, a 38.66% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
NSE: SUPRIYA.NS

Supriya Lifescience Limited

CEO Dr. Satish Waman Wagh
IPO Date Dec. 28, 2021
Location India
Headquarters 207/208 Udyog Bhavan
Employees 448
Sector Health Care
Industries
Description

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, anti–hypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.

Similar companies

AMIORG.NS

Ami Organics Limited

USD 23.42

2.77%

LATENTVIEW.NS

Latent View Analytics Limited

USD 5.14

1.64%

DATAPATTNS.NS

Data Patterns (India) Limited

USD 24.83

3.03%

TARSONS.NS

Tarsons Products Limited

USD 4.57

1.60%

MEDPLUS.NS

MedPlus Health Services Limited

USD 8.96

-4.78%

StockViz Staff

January 15, 2025

Any question? Send us an email